Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Eitemau Tebyg

• Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
  gan: Handlos Grauslund, Jacob, et al.
  Cyhoeddwyd: (2021)
• The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
  gan: Morten Orebo Holmström, et al.
  Cyhoeddwyd: (2016)
• Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
  gan: Klausen, Uffe, et al.
  Cyhoeddwyd: (2018)
• The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy
  gan: Holmström, Morten Orebo, et al.
  Cyhoeddwyd: (2017)
• Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
  gan: Jørgensen, Nicolai Grønne, et al.
  Cyhoeddwyd: (2020)